State of the Art Liver Imaging in Cirrhosis 2021

The second-leading cause of cancer-related mortality in the world and the third most common cause of death among patients with cirrhosis, hepatocellular carcinoma (HCC) develops at a fairly constant rate—approximately 3% per year, regardless of cirrhotic stage. This Online Course covers the imaging of diffuse liver diseases that often result in HCC, as well as the various pitfalls and mimics leading to misinterpretation.

Learning Outcomes and Lectures

After completing this course, the learner should be able to:

• Describe the current Imaging update of diffuse liver diseases.
• Discuss the evolution of LI-RADS with current practice and future perspectives.
• Illustrate various pitfalls and mimics which can hinder the diagnosis of observations in cirrhosis.
• Discuss the use of Gadoxetate Disodium in patients with cirrhosis.

• Imaging of Diffuse Liver Diseases—K. Fowler
• LI-RADS: The Past, Present, and Future—C. Sirlin
• Pitfalls and Misdiagnoses in Cirrhosis—K. Elsayes
• Use of Gadoxetate Disodium in Patients with Cirrhosis—V. Chernyak